Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
By J. Sanders, M. Monogue, T. Jodlowski, J. Cutrell. Journal of the American Medical Association (JAMA), 2020
2,458 citations recorded by the source corpus.
Importance The pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge to identify effective drugs for prevention and treatment. Given the rapid pace of scientific discovery and clinical data generated by the large number of people rapidly infected by SARS-CoV-2, clinicians need accurate evidence regarding effective medical treatments for this infection. Observations No proven effective therapies for this virus currently exist. The rapidly expanding knowledge regarding SARS-CoV-2 virology provides a significant number of potential drug targets. The most promising therapy is remdesivir. Remdesivir has potent in vitro activity against SARS-CoV-2, but it is not US Food and Drug Administration approved and currently is being tested in ongoing randomized trials. Oseltamivir has not been shown to have efficacy, and corticosteroids are currently not recommended. Current clinical evidence does not support stopping angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients with COVID-19. Conclusions and Relevance The COVID-19 pandemic represents the greatest global public health crisis of this generation and, potentially, since the pandemic influenza outbreak of 1918. The speed and volume of clinical trials launched to investigate potential therapies for COVID-19 highlight both the need and capability to produce high-quality evidence even in the middle of a pandemic. No therapies have been shown effective to date.
Subfields: Infectious Diseases, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/70c5bb96f1cb96c9983e611d312c6403f37b750c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Miriam Merad
- N. Bhardwaj
- Brian D. Brown
- Nicolas Vabret
- Yuan Huang
- Kristijan Skok
- Verena van der Heide
- C. Gruber
Citations in the corpus
- Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy. (2020, neutral): “Length of hospital stay, median (IQR), d 22 (12-42) 12 (8-19) 39 (24-61) 79 (74-84) <.”
- Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19 (2020, background): “Although a large number of studies and clinical trials are being launched on COVID-19 around the world [2, 3], no evidence from randomized clinical trials has shown that any potential therapy improves outcomes in patients [4].”
- Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome: Results From a Prospective, Single-Center, Clinicopathologic Case Series (2020, background): “In light of the currently limited options for effective antiviral treatment, it may be critical to better understand the morphologic basis for severe and fatal COVID-19 outcomes (21).”
- Immunology of COVID-19: Current State of the Science (2020, positive): “Other studies have reported associations with delayed viral clearance and increased complications in SARS and MERS patients (Sanders et al., 2020) .”